Mycobacterium tuberculosis Beijing type mutation frequency

Emerging Infectious Diseases

Volumn 19, Issue 3, 2013, Pages 522-

  Werngren, Jim ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

BACTERIAL MUTATION; COLONY FORMING UNIT; GENOTYPE; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84874284903     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1903.121001     Document Type: Letter

References (5)

1. de Steenwinkel JEM, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype, association with MDR TB. Emerg Infect Dis. 2012;4:660-3.
2. David, HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810-4.
3. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol. 2003;41:1520-4. http://dx.doi.org/10.1128/JCM.41.4.1520-1524.2003
4. Bergval I, Kwok B, Schuitema K, Kremer K, van Soolingen D, Klatser P, Anthony R. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS ONE. 2012;7:e29108. http://dx.doi.org/10.1371/journal.po ne.0029108
5. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46:267-74. http://dx.doi.org/10.1128/AAC.46.2.267-274.2002